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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic obstructive pulmonary disease (COPD) is a major 
worldwide health problem that has an increasing prevalence 
and mortality (1, 2). Oxidative stress, which can be defined as 
an increased exposure to oxidants and/or decreased antioxi-
COPD is an obstructive airway disorder characterized by a 
slowly progressive and irreversible decrease in FE V ( (I, 2, 7). 
FEV| decreases are caused by a narrowing of airway lumen di­
ameters that develops as a result of varying perturbations in
both airway and interstitial lung tissue. Airway abnormalities 
consist of increased wall thickening, intraluminal mucus accu­
mulation, smooth muscle hypertrophy, and small airway lining 
fluid changes. Additional early lesions include inflammatory 
cell infiltration and goblet cell metaplasia.
The tissue component of emphysema is defined anatomi­
cally as the permanent destructive enlargement of airspaces 
distal to the terminal bronchioles with a concomitant loss of 
alveolar attachments (7). Emphysema is recognized in vivo by 
a decreased diffusing capacity (D lco) and reduced lung pa­
renchymal density on chest radiograph and high-resolution 
computerized tomography.
Chronic bronchitis, a frequent feature of COPD, is a persis­
tent recurrent bronchial hypersecretion that causes expectora­
tion on most days for a minimum of 3 mo per year for at least 
two successive years (7). The pathology of chronic bronchitis 
is not unequivocal but primarily includes large airway mucus 
gland hyperplasia and inflammation; however, hypersecretion 
may occur without airway obstruction.
Patients with COPD often manifest some reversibility of 
airway obstruction following treatment with bronchodilators 
and airway hyperresponsiveness when given constrictor stim­
uli (8). These similar features often cause difficulties in differ­
entiating COPD from asthma, especially in older patients. 
However, asthma is usually not related to cigarette smoking, 
and the reversibility of the obstructive pattern and airway hy­
perresponsiveness is a more common and more prominent oc­
currence in asthma than in COPD. In addition, emphysema 
and chronic hypoxemia are usually absent in asthma (<S, 9).
Prevalence and Clinical Course
dant capacities, is widely recognized as a central feature of COPD is rare before the age of 4», bul alter that age symp- 
many diseases (3, 4). Considerable evidence now links COPD toms of hypersecretion occur with increasing frequency. Per- 
with increased oxidative stress (5, 6). The purpose of this re- sistent airflow obstruction becomes more common at around
view is to describe the role and origin of the oxidant-antioxi- 
dant disturbances that participate in the development of COPD. 
Our presentation also addresses ways of assessing the contri­
bution of oxidants and identifies therapeutic approaches that 
could improve cellular oxidant-antioxidant balance in 
lungs of COPD patients.
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age 60. The prevalence of COPD then increases progressively 
until 60-70 yr of age when, in large part due to mortality, it be­
comes more stable. The distribution of COPD in the United 
States and western Europe shows a similar pattern with re­
spect to age, with an estimated prevalence of more than 10% 
in individuals who are at least 50 yr of age. The greater preva­
lence of COPD in men has diminished recently because of in­
creased smoking by women (10).
The clinical manifestations and progression of COPD are 
influenced by a number of presumed risk factors, which in-
: alphaj-antitrypsin re c u r r e n t bronchopulmo­
nary infections, air pollution, socioeconomic status, lower
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birth weight, and a history of severe childhood respiratory in- The contribution of iron has become increasingly meaning-
fections (11, 12). However, the most striking relationship is fui in understanding the development of COPD. Iron concen- 
between cigarette smoking and COPD. Nearly 90% of all trations were increased in alveolar macrophages (AM) of cig-
COPD patients are smokers (12, 13). Yet, for unknown rea­
sons, only about 20% of cigarette smokers develop COPD.
arette smokers, and lung lining fluids obtained from cigarette 
smokers contained substantially more iron than specimens
Smoking may also compound the detrimental effects of in- from nonsmokers (16). Excess iron also appeared to be con-
haled environmental toxins, and vice versa (14).
Because the symptoms and signs of COPD are variable and
centrated in the upper lobes of cigarette smokers (17). The 
source of the increased iron in lungs of smokers is unknown,
often attributed mistakenly to increasing age or other condi- but each cigarette contains 0.042 |xg of iron (18). Iron also ac­
tions, abnormalities in pulmonary function are frequently di- cumulates progressively with age in men and in postmeno-
agnosed very late or not at all. This is regrettable since earlier pausai women—intriguingly, at the time when COPD worsens
diagnosis could be made by measurement of pulmonary func­
tion. Assessment of FEV¡/FVC is considered the most sensi­
tive indicator for early airway obstruction, and an accelerated 
decline in pulmonary function can be reliably detected from 
repeated yearly measurements. Obviously, a great need exists 
for more effective smoking cessation approaches and/or a safe 
drug that could reduce the annual decline in FEVj in COPD 
patients.
OXIDATIVE STRESS AND COPD
Oxygen Radical-Antioxidant Chemistry
The well-described chemistry of oxygen radicals and antioxi­
dants is depicted in Figure 1 (4, 15). Superoxide anion ( 0 2~) 
formation from oxygen is the first step. OjT is generated pri­
marily by mitochondrial metabolism, molybdenum hydroxylase 
(xanthine, sulfite, and aldehyde oxidases) reactions, arachi- 
donic acid metabolism, and NADPH oxidase-dependent pro­
cesses in phagocytic cells. Reaction of 0¿~ and hydrogen per­
oxide (H20 2) in the presence of transition metal, usually ferrous 
iron (Fe++), produces the hydroxyl radical ( ’OH). When cata­
lyzed by neutrophil myeloperoxidase (MPO), H 20 2 and a chlo­
ride form hypochlorous acid (HOC1). 'O H  and HOC1 are em­
phasized because both are extremely potent oxidants. H20 2 
gains significance as a central precursor to both OH and
HOC! (3, 4,15).
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in both sexes (Figure 2) (19). AM from cigarette smokers also 
released more iron than AM from nonsmokers in vitro (20). In 
addition, saturated free fatty acids (mainly stearic and pal­
mitic) concentrated from cigarette smoke bound and trans­
ferred ferrous iron into organic phases (21) and enhanced pro­
duction of HOCJ by stimulated polymorphonuclear neutrophils 
(PMN) in vitro (22). Because of its high reactivity, iron is nor­
mally bound to various iron-binding compounds, such as trans­
ferrin, ceruloplasmin, and ferritin (23). However, this protec­
tive mechanism may be disturbed in the lungs of COPD patients, 
since cigarette smoke and oxidants can release iron from fer­
ritin (24,25).
Pulmonary antioxidant defenses are widely distributed and 
include both enzymatic and nonenzymatic systems (3, 4). The 
major enzymatic antioxidants are superoxide dismutase (SOD), 
which degrades 0 2 and catalase, and the glutathione (GSH) 
redox system, which inactivates H20 2 and hydroperoxides 
(Figure 1). Three forms of SOD may be important: manga­
nese SOD, which is located in mitochondria, Cu-Zn SOD, 
which resides in the cytoplasm, and extracellular SOD, which 
lines blood vessels. Another important element is glutathione 
(GSH), which is a water-soluble, low-moiecular-weight tripep­
tide (L-"y-glutamyl-L-cysteinyl glycine) that is present in high 
concentrations in each cell. GSH is also present extracellularly 
and is particularly abundant in lung epithelial lining fluids 
(ELF). Indeed, GSH concentrations in ELF exceed plasma 
levels by approximately 100-fold (26, 27). In its antioxidant ca­
pacity, GSH forms intermolecular disulphide nonradical end- 
product-oxidized glutathione (GSSG). GSH is also a cofactor 
for various enzymes that decrease oxidative stress (3,4,15). In
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Figure 7. Basic oxygen radical and antioxidant chemistry.
Figure 2. Iron storage as a function of aging. Progressive increases 
in iron occurred as a function of aging in men and postmenopaus- 
ally in women. (Adapted by permission from Reference 19.)
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contrast, GSSG is either exported from the cell or converted 
to GSH by a reductase reaction that obtains electrons from 
NADPH (Figure 1). Vitamin E, ß-carotene, vitamin C, uric 
acid, flavonoids, and bilirubin are some of the nonenzymatic 
factors that may function as antioxidants (3,4).
Contribution of Oxidants to COPD
The earliest clue regarding the pathophysiology of COPD was 
the landmark observation that individuals with congenital 
a r antitrypsin deficiency developed emphysema prematurely, 
especially if they smoked cigarettes (28). This finding pointed 
convincingly not only to a role for elastase but also for oxi­
dants in COPD because a r-antitrypsin needed to be inacti­
vated by oxidants for elastase to be toxic (29-32). The latter
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discovery also explained why emphysema developed in indi- Figure 3. XO-mediated mucus secretion. XO-generated 0 2 radi-
viduals who did not have a genetic defect in a r antitrypsin cals increased release of mucus (high-molecular-weight glycocon-
jugates) from guinea pig epithelial cells in culture. (Adapted by
permission from Reference 46.)
(30-32). Subsequently, it was shown that cigarette smoke, per- 
oxynitrite, phagocyte, and chemically generated oxidants could 
inactivate antiproteases in vitro (33-35). In addition, stimu­
lated alveolar type II epithelial cells and AM (but not fibro­
blasts) from guinea pigs inactivated ot]-proteinase inhibitor in
the presence of MPO (36). The susceptibility of the a,-anti- mation, reduce surfactant activity, injure fibroblasts, and pro­
trypsin methionine site to oxidative injury and the finding that duce numerous other effects that might diminish pulmonary 
some cigarette smokers had increased levels of ctt-antitrypsin lung mechanics and/or lung repair mechanisms in patients 
with oxidized methionine sites in their lung lavages further im- with COPD (48-50). Oxidants also promote epithelial perme- 
plicated oxidant inactivation of ot]-antitrypsin as a precursor ability (51, 52). Oxidants in cigarette smoke even reduce 0¿ 
of elastase-dependent tissue damage in vivo (37,38). The prin- generation by PMN in vitro (53). Treatment of endothelial 
ciple was well demonstrated by studies showing that prior ex- cells with plasma exposed to cigarette smoke activates the 
posure to a small, noninjurious dose of H20 2 remarkably in- pentose phosphate pathway metabolism, increases GSH ex­
creased the susceptibility of isolated lungs to injury caused by trusión, decreases ATP levels, and releases angiotensin-con- 
perfusion with neutrophil elastase. In contrast, neutrophil verting enzyme (ACE) (54). These findings were corrobo- 
elastase was not appreciably toxic in the absence of oxidant rated by findings showing that airway obstruction, reflected by
preexposure (39). Additional cardinal aspects in the under­
standing of COPD were the observations that some cigarette
reduced FEV¡ levels, correlates with GSH, MPO, and eosino­
philic cationic protein (ECP) levels in COPD patients (55),
smokers had increased elastase in their lung lavages and that and that treatment with manganese SOD reduces cigarette 
intratrachealiy instilled human neutrophil elastase or protein- smoke-induced cytotoxicity (56).
ase 3 caused emphysema in animals (37,40-43).
More needs to be done to validate the protease-antipro- 
tease theory of COPD (32), but many aspects of the patho­
physiology of COPD are consistent with the potential conse­
quences of increased lung concentrations of elastase (30). For 
example, elastase can damage airspaces by degrading elastin 
and a variety of extracellular membrane proteins, proteogly­
cans, and glycoproteins. Elastase can also stimulate inflamma­
tion by increasing interleukin-8 (IL-8) synthesis, impair heal­
ing by inactivating cytokines and growth factors, and produce 
surfactant abnormalities by cleaving surfactant apoproteins. 
Additionally, elastase can activate or inactivate various other
, inhibitors of neutrophil collagenase, and secretory 
leukoprotease proteinase inhibitor (SLPI)—an inhibitor of 
neutrophil elastase (44)— and in that way further modulate in­
flammation. Cigarette smoke and/or elastase-rnediated dam­
age to lung connective tissue structural elements and loss of 
parenchyma produces overly compliant lungs, early airway 
closure during expiration, and air trapping, which most likely 
contribute to the distended, hyperlucent lungs of COPD pa­
tients (45).
This historically relevant and pioneering mechanism needs 
to be viewed in combination with the direct toxicity of oxi­
dants to key lung structures, such as lung connective tissue ele­
ments. Oxidants can not only damage DNA, lipids, and pro­
teins (3, 4), but also mediate a variety of processes that could 
foster the development of COPD. For example, oxidants in­
crease high-molecular-weight gly cocon jugate (mucus) produc-
SOURCES OF OXIDANTS
Cigarette Smoke
Cigarette smoke is a rich source of oxidants (Figure 4) (57- 
62). The tar component of cigarette smoke (particulate matter 
that may be decreased by filters) contains an estimated 10IR
k
Cambridge filter - a glass fiber filler Cheti retains 
Wfo of particles larger than 0 . 1 |im
*>» p ; -< m  rñ i-f,.
cigarette
Elud ís
g a s  1*1! ASB
ClCIARlîTTK SMOK 6
WIKirmllWww
TAU
ru u  m n tm i^n T u n m  im* M  immu >ir nmw n w i w ui iy i» «
O /  semkjumone radical on filter
Y
NO, NOi, R1. KOO* 
KOONO* KOONOj
«
I 
I 
I 
I 
I  
I 
I 
%
4 
4 
I 
i  
I 
I 
I 
I 
♦
I
Aqueous cig tar
.....  . . . .  W -
solutions (ACT)
Y
— iY~
« ■ tM
Nm
Hcmoüiderin-likc pigments
lUirtrpi'M
Figure 4. Components of cigarette smoke. Cas-phase smoke con­
tains both carbon-centered and oxygen-centered radicals that are
tion by epithelial cells in culture (Figure 3) (46) and impair produced from N 0/N 02 reactions with reactive compounds in 
cilia function (47). Oxidants also stimulate thromboxane for- smoke. (Adapted by permission from Reference 57.)
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spins/gram of tar. These cigarette smoke-generated radicals adhesion molecule-1 (ICAM-1) and circulating E-selectin lev­
are sufficiently stable to be detected by electron spin reso- els were increased in COPD patients and probably altered 
nance. One of these radicals is the semiquinone radical that PMN retention in the lung (93). In addition, neurokinin (NK,)
reduces oxygen to 0¿ . By comparison, the inhaled gas com­
ponent of cigarette smoke may contain as many as IQ15 or-
receptors mediated cigarette smoke-induced adhesion of PMN 
(and eosinophils) to the endothelium of venules in the rat tra-
ganic radicals per puff. The latter radicals are highly reactive, cheal mucosa (94).
short-lived (< 1 s), carbon- and nitrogen-centered species. Recruitment and activation of PMN and other inflamma-
Gas phase smoke also contains high concentrations of reactive tory cells into the lung may also involve production by AM,
olefins and dienes. As much as 500 ppm of nitric oxide (NO) epithelial, or other lung cells (95, 96) of interleukin-8 (IL-8).
exists in cigarette smoke, and cigarette smoke converts ty- IL-8 levels were increased in sputum recovered from COPD
rosine to 3-nitrotyrosine and dityrosine in a reaction that can patients compared with nonsmoking control subjects, ciga-
be inhibited by GSH, ascorbic acid, or uric acid (63). Exposure rette smokers, and asthmatic patients (Figure 5) (97). IL-8 is a
to cigarette smoke also rapidly upregulated lung NO synthase potent chemotaxin for PMN in vitro. Another AM and lung
activity in rats (64, 65). Peroxynitrates from the reaction of cell-derived molecule that may contribute to PMN recruit-
NO and O f  (4) can also be formed under these circum- ment is LTB4 (98). In addition, nicotine, a chemoattractant for
stances, but their fate and role in COPD are uncertain. Fi- PMN in vitro, may attract PMN into the lung (99), prevent the 
nally, oxidants may increase the toxicity of nitrosamines (66). reduction in PMN deformability induced by cigarette smoke 
(100), and/or even prolong PMN survival by suppressing apo-
Inflammation
The coexistence of airway and parenchymal inflammation in 
most patients with symptomatic chronic airflow limitation ef­
fectively connects inflammation with COPD (67). Airway as- eral blood leukocyte counts elaborated more O f  than PMN 
sessments performed by sputum analysis, bronchoscopy, bi- recovered from nonsmokers or PMN recovered from smokers 
opsy, and lung lavage, in some cases separating initial from who have normal circulating leukocyte counts (Figure 6)
The 0 2 radical-producing activity of PMN that are lodged 
within the lungs of COPD patients is unknown, but PMN re­
covered from the blood of smokers who have elevated periph-
subsequent samples, have all suggested that inflammation 
contributes to the development of COPD (68-72). Inflamma­
tion may not only be responsible for mild airflow limitation 
and bronchiolar constriction but also may cause fibrosis, gland 
hypertrophy, and chronically increased smooth muscle tone.
Furthermore, by increasing connective tissue deposition and report (106), circulating 0¿” release from PMN correlated
(102). In addition, PMN recovered from some COPD patients 
had enhanced chemotaxis, proteolytic, and MPO activities in 
vitro (103, 104). Similarly, individuals subjected to passive 
smoking also had increased circulating leukocyte counts and 
cells that released more oxidants (105). Additionally, in one
by decreasing the supporting alveolar structure of the outer with bronchial hyperactivity in COPD patients, while in an-
wall of the small airways, inflammation may further amplify other report (107), Oj generation from PMN was increased
airway limitation by deforming and narrowing the airway lu- during acute infectious exacerbations. Increased numbers of
men (73-78). Most observations relating to inflammatory cells PMN appear to be making increased amounts of oxidants in 
in COPD have focused on PMN and AM, but eosinophils, the lungs of COPD patients (108). 
lymphocytes, and other cells undoubtedly impact the inflam­
matory process and may alter oxidant-antioxidant balance 
(79-82).
Neutrophils (PMN). Biopsies from the lungs of COPD pa­
tients and specimens from peripheral airway walls of smokers 
contained increased numbers of neutrophils. Moreover, lungs 
of smokers with airway obstruction had more PMN than 
smokers without airway obstruction (56,83,84). Since lung la­
vage and sputum analyses most likely reflect situations in the 
respiratory bronchioli and alveoli (85), it is not surprising that 
PMN were increased in lung lavage and sputum specimens 
from smokers with COPD (86). Furthermore, the degree:  of
airway obstruction and the number of recovered PMN ap­
peared to be related to the amount smoked in most individu­
als (71,83).
Many mechanisms could account for the increased num­
bers of PMN that accumulate in the lungs of cigarette smokers 
with COPD. For example, PMN transit time was delayed in 
lungs immediately after smoking (87). In addition, oxidants 
decreased PMN deformability and, as a result, may enhance 
PMN sequestration in small blood vessels (88). More PMN 
may adhere where lung blood vessels are damaged and flow is 
abnormally low because of lung injury (89). Cigarette smoking 
also elicited CuZn SOD inhibitable adhesion of PMN to cul­
tured hamster endothelium (90), and CD!8 integrins were in­
creased on the surface of sequestered PMN in the pulmonary 
vessels of rabbits exposed to cigarette smoke (91 ). Upregula- 
tion of E-selectin expression also occurred in patients with
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Figure 5. Inflammatory mediators in COPD sputum. COPD pa­
tients had increased TNFot and IL-8 levels in their induced sputum
chronic bronchitis, and adhering PMN were associated with compared with control subjects, smokers, and asthmatic patients. 
E-selectin activity in lung vessels (92). Circulating intercellular (Adapted by permission from Reference 97.)
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Figure 6. Superoxide production by neutrophils from cigarette 
smokers. Neutrophils from cigarette smokers with circulating leu­
kocytes exceeding 9,000 made more O f  than neutrophils from 
smokers with circulating leukocytes of less than 9,000 or non- 
smokers. (Adapted by permission from Reference 102.)
Alveolar macrophages. Because of their strategic location 
and robust effector capabilities, AM may be pivotal in the de­
velopment of COPD. More AM were recovered from the 
lungs of smokers, and these AM appeared to be activated 
since they were larger, stickier, and contained more pig­
mented cytoplasmic inclusions than AM from nonsmokers 
(109, 110). Increased AM pigmentation has also been associ­
ated with poor lung function (111).
Numerous mechanisms, such as those described for PMN, 
probably contribute to the recruitment of monocytes and their 
maturation into AM in lungs of patients with COPD (112-115). 
In addition, elastin fragments were increased substantially in 
lungs of cigarette smokers and are selective chemotaxins for 
monocytes in vitro (116). Prostaglandin F2a and thromboxane 
B2, most likely derived from activated AM, were also increased 
in lung lavages of smokers and may facilitate inflammatory re-
AM recovered by lung lavage from healthy young cigarette 
smokers released more 0¿ than AM from nonsmoking con­
trol subjects in vitro (Figure 7) (118-120). In addition, sub- 
populations of higher density AM were increased in smokers 
compared with nonsmokers and were responsible for the in­
creased CD.il/CD18 positivity and enhanced Oj
of AM from smokers (121). Spontaneous release of increased 
amounts of H202 from smoker monocytes has also been ob­
served and related to accelerated maturation and activation
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Figure 7. Superoxide production by alveolar macrophages from 
cigarette smokers. AM recovered by lung lavage from asymptom­
atic smokers made more than AM from nonsmokers. 
(Adapted by permission from Reference 118.)
(122). Exposure to tobacco smoke in vitro also increased AM 
oxidative metabolism (123).
Eosinophils. Peripheral blood eosinophilia has been identi­
fied as a risk factor for the development of airway obstruction 
and a negative prognostic sign in newly diagnosed patients 
with chronic bronchitis (124, 125). Moreover, airway wall bi­
opsies of patients with COPD contained increased numbers of 
eosinophils (79), and lung lavages from COPD patients had 
increased levels of eosinophilic cationic proteins (ECP), a 
marker of eosinophil activation (126). Furthermore, revers­
ibility of airway obstruction correlated with bronchial eosino­
philia in patients with very severe airflow limitation and emphy­
sema, suggesting that eosinophils may contribute to pulmonary 
oxidative stress. This impression is also supported by observa­
tions that eosinophils make much more OV than PMN or AM 
in vitro (127-130). For example, in response to phorbol myristate 
acetate (PMA), normal human eosinophils generated signifi­
cantly more 0 2 (14.1 ± 3.3 nmol of cytochrome C/10 min/ 
5 X  IO5 cells) than matched neutrophil fractions (5.9 ± 0.9 nmol/ 
20 min/5 X  10s cells) (127). By comparison, PMA-stimuIated 
human neutrophils (1.5 ± 0.8 nmol/20 min/5 X  10*’ cells) made 
more 0 2 than PMA-stimulated human AM (8.6 ± 1.0 nmol/ 
20 min/5 X  1 i f  cells). Although the relationship that eosino­
phils generate more 0 2 than PMN, which generate more O? 
than AM, generally holds true, the pattern is dependent on 
the stimulus (127).
Xanthine oxidase. Xanthine oxidase (XO), which generates 
0¿~ and H20 2, was increased in lungs of rats exposed to ciga­
rette smoke (131). Lung XO increases might reflect conver­
sion of xanthine dehydrogenase (XD) to XO by elastase or 
oxidants and/or increased synthesis of XD (132). XO was also 
increased and associated with increased leukocyte adhesion 
and erythrocyte (RBC) hemolysis in hamsters exposed to cig­
arette smoke (90). Reaction of XO-derived 0 2 metabolites 
with serum forms chemotaxins for PMN and thereby might be 
another mechanism responsible for recruiting PMN to the 
lungs of cigarette smokers (133). Moreover, XO activity was 
increased in cell-free lung lavages from COPD patients com­
pared with nonsmoking normal subjects and associated with 
increased OV generation, clastogenie (DNA damaging) activ­
ity, and uric acid production (Figure 8) (134). Increased lung 
XO activity could contribute to the increased exhaled H20 2 
levels of cigarette smokers (135).
Other sources, increased numbers of lymphocytes, epithe­
lial, mast, and other metabolieally active lung cells that con­
sume oxygen probably release 0 2 radicals that could alter oxi- 
dant-antioxidant balance in the lungs of patients with COPD 
(Figure 9) (3, 4, 36). Mitochondrial and araehidonic acid me­
tabolism also can generate oxidants that might participate in 
the development of COPD (34).
Infections
Infections may contribute to oxidative stress in patients with 
COPD by facilitating the recruitment and activation of phago­
cytic cells in the lung
nonencc .S' //
’occus pneumoniae and
’ing ex­
acerbations and remissions of COPD ( 137—140), and 0 2 pro­
duction by blood neutrophils was increased in COPD patients 
during acute exacerbations and then returned to normal dur­
ing recovery (141). Even clinically stable COPD patients are 
colonized with bacteria that might stimulate phagocytic cell 
oxidant production. The bronchi of 50% of COPD patients
are colonized with bacteria belonging to the normal oropha­
ryngeal flora (138, 142). Bacterial adherence may favor bacte­
rial persistence and colonization of the respiratory tract (143,
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Figure 8. Factors associated with increased lung lavage XO activity 
in COPD patients. Cell-free lung lavages from COPD patients had 
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activity, O f  production, and uric acid production compared with 
lavages obtained from control subjects. (Adapted by permission 
from Reference 1 34.)
a -1 -Proteinase 
Inactivation
With MPO 
(%)
Cells
Figure 9. Oxidant production by cultured lung cells. Type II cells 
and AM released more 0¿~ and H20 2 and inhibited ar proteinase 
activity (with MPO) better than fibroblasts. (Adapted by permis­
sion from Reference 36.)
Antioxidant Decreases
One study found that erythrocytes (RBC) from some smokers 
had decreased G6PD and GPX activity and were more sus­
ceptible to lipid peroxidation in vitro than RBCs from non- 
smokers (148). Similarly, RBCs from the children of smoking 
parents were peroxidized more readily in vitro than RBCs 
from the children of nonsmokers, and this tendency was re­
versed by vitamin E treatment (149). RBCs from children with 
smoking parents also had decreased G6PD, GPX, and SOD
a m t ia v in a MT r i le n  iDDAKirtc activities compared with RBCs recovered from the childrenANTIOXIDANT DISTURBANCES , .  1 , , . .or nonsmoking parents (149). In addition, cigarette smoking 
Because oxidants play such a pronounced role in cigarette has been associated with decreased plasma ascorbate, plasma
144), and smokers had an enhanced adherence of S. pneumo­
niae to their buccal cells in vitro (145). In addition, H. influen­
zae adhered more to the pharyngeal cells of smokers with 
chronic bronchitis than healthy subjects (146).
smoke-induced lung damage, the status of pulmonary antioxi- ß-carotene, and vitamin C levels (150-160). Additionally, vita-
dant defense mechanisms assumes paramount importance (3, min E levels were lower in the lung lavages of young asymp- 
4, 15). In 1986, Taylor raised the question, “Is antioxidant de- tomatic smokers, and this deficiency was linked with enhanced
ficiency related to chronic obstructive pulmonary disease'/; AM cytotoxicity (Figure 10) (161-165). Establishing the rela-
and reported a relationship between a deficiency in plasma tionship between decreased antioxidant capacity and smoking
antioxidant activity and an abnormal FEV^FVC ratio in pa- remains difficult because many confounding variables, such as 
tients with COPD (147). Subsequently, a number of antioxi- life-style, diet, and social class, may alter both smoking and 
dant disturbances have been observed in COPD patients, but changes in antioxidant levels.
a notable inconsistency exists, and the findings are difficult to 
compare because of the different designs of the various stud­
ies. Some examples of both antioxidant decreases and in­
creases include the following observations.
Antioxidant Increases
A number of studies have revealed increased antioxidants in 
cigarette smokers. For example, vitamin E and C levels were
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Figure 10. Vitamin E levels in lung lavages of cigarette smokers. 
Cigarette smokers have decreased iung lavage vitamin E levels 
compared with nonsmokers. Lung lavage vitamin E levels in­
creased following oral therapy with vitamin E for 3 wk. (Adapted 
by permission from Reference 164.)
ne synthetase—the rate-limiting enzyme in GSH 
synthesis—was also increased in human alveolar epithelial 
cells following exposure to cigarette smoke
The increased antioxidant activity in RBCs and lungs of 
cigarette smokers and the increased activity of SOD and cata- 
lase activities in lungs of rats and hamsters exposed to ciga­
rette smoke are both reminiscent of protective antioxidant re­
sponses that occur in oxidative “tolerance” models (185). 
Tolerance is not a well understood phenomenon, but it ap­
pears that an antecedent low-grade oxidative stress can confer 
a subsequent adaptive resistance to oxidative stress, 
by increasing antioxidant defenses (3, 4, 186). Thus, if oxidant 
stress contributes to COPD, then adaptive increases in antiox­
idants may be protective and explain why some cigarette smok­
ers do not develop COPD. Indeed, certain cigarette smokers, 
for genetic or other reasons, may respond by increasing their
mtioxidant Responsive),
increased in the plasma and internal mammary arteries of cig-
smokers, for unknown reasons, do not increase their lung anti­
oxidants
Consistent with the tolerance premise was the finding that 
individual measurements of GSH levels in RBC and ELF of 
cigarette smokers showed great individual variability. There­
fore, it is possible that individuals with absolutely or relatively 
lower GSH and other compensating responses are more sus­
ceptible to COPD, while individuals with enhanced antioxi­
dant responses are less susceptible to COPD (187-189). A 
case in point exists in patients with tobacco smoke-induced
arette smokers compared with nonsmokers, and the smokers optic neuropathy who did not develop the increased GSH lev­
els found in cigarette smokers who do not develop the ocular 
disorder (190). Thus, adaptive increases in antioxidants in cer­
tain individuals may be a valuable protective mechanism 
against COPD induced by cigarette smoke (186,191).
with higher vitamin C levels had lower levels of lipid peroxida­
tion (166, 167). In certain smokers, oxidatively stressed AM 
appeared to accumulate vitamin C and perhaps other antioxi­
dants (168). This may be beneficial since treatment with vita­
min C prevented cigarette smoke-induced leukocyte aggrega­
tion and adhesion to hamster endothelium in skinfolds (169) 
and altered biochemical responses in rats (1.70). In another 
study, vitamin C intake improved the lung function of ciga- A number of abnormalities and measurement of biomarkers
INDICATORS OF OXIDATIVE STRESS
have suggested that increased oxidative stress is occurring and 
is detrimental in cigarette smokers with COPD. The most con­
vincing way to determine the involvement of oxidative stress 
in COPD is to directly measure oxygen radicals in lung tissue
rette smokers, asthmatics, and bronchitics (171). Nonetheless, 
in a recent trial, ß-carotene treatment may have accelerated 
the development of lung cancer in cigarette smokers (172,173).
Additional endogenous mechanisms may increase antioxi­
dant levels in certain smokers. Certain cigarette smokers had 
increased GSH and glutathione peroxidase activities in their 
ELF compared with nonsmokers (26, 27, 174, 175). These in- electron spin resonance and other direct techniques cannot be 
creased GSH levels in ELF from human smokers are consis- easily applied to the lung. The alternative has been to measure
or
oxygen n
air. measurement is
tent with the high GSH levels observed in animals exposed to damage inflicted by oxygen radicals upon various lung bio­
cigarette smoke and may be functionally important since re- molecules, usually lipids, proteins, or DNA. Some of the ap-
ducing lung GSH increased lung epithelial permeability (175- 
179). For example, cigarette smoke and its condensates caused 
an oxidant-induced injury to A549 human type II alveolar epi­
thelial cells (reflected by impaired attachment, decreased pro­
proaches that have been used which indicate that oxidative 
stress is occurring in COPD are described below.
liferation, and lysis), which was reversed by adding GSH ex- 
tracellularly and worsened by depleting GSH intracellularly 
with buthionine sulfoxamine (177). Moreover, reduced FEV| 
levels correlated with decreased lung lavage GSH levels in 
smokers with chronic bronchitis, underscoring the importance 
of adequate GSH levels in COPD. GSH levels were also in­
creased in RBCs from certain cigarette smokers compared 
with nonsmokers. Adding RBCs from cigarette smokers pro­
tected cultured endothelial cells against damage by H20 2 bet­
ter than adding RBCs from nonsmokers (180). Catalase activity 
in RBCs can decrease oxidative inactivation of a,-antitrypsin 
by cigarette smoke, further indicating that alterations in RBC 
antioxidants may be meaningful (181). In related observations, 
cigarette smoking increased lung SOD, catalase, and glutathione 
peroxidase activities, but these responses did not protect the 
rats against cigarette smoke (182, 183). mRNA for gamma-
H20 2 Exhalation
During acute exacerbations, patients with
more H20 2 by
exhaled
% than stable ex-smokers with COPD or 
normal subjects (Figure 11) (135). The source of the exhaled 
H 20 2 was unknown (192), but AM from smokers released sig­
nificantly more 0¿ than AM from nonsmokers (1 , and
AM recovered by lung lavage from subjects with a recent 
lower respiratory tract infection released more H20 2 in vitro 
(122). Additionally, smokers had increased lung lavage XO
Lipid Peroxidation
Free radicals trigger lipid peroxidation chain reactions by ab-
bon
Î a hydrogen atom from a side-chain me 
-198). The res 
reacts with 0-> in
radical
cells to give a peroxyl radical
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Figure 12, Free F2-isoprostanes in cigarette smokers. F2-isopros- 
tanes were increased in cigarette smokers compared with non- 
smokers. F2-iso prosta ne levels decreased following smoking cessa­
tion. (Adapted by permission from Reference 212.)
smokers, consistent with the possibility that certain individuals 
are more resistant to oxidative stress, perhaps as a consequence 
of their enhanced antioxidant defenses (212).
that subsequently propagates a chain reaction which trans- DNA Damage
forms polyunsaturated fatty acids (either as free acids or as Many different compounds in cigarette smoke can readily re­
part of lipids) into lipid hydroperoxides. Lipid peroxidation act directly to form radicals, while other substances (procar-
(LPO) can impair membrane function, inactivate membrane- cinogens) must be activated by one or more of the p-450 cyto-
bound receptors and enzymes, disturb membrane fluidity, and 
increase permeability (193). Lipid hydroperoxides can also in­
teract with antioxidants (such as a-tocopherol) or decompose 
after reacting with metal ions (such as iron or copper) or iron
chromes before becoming electrophilic species that enter into 
damaging interactions which produce single-strand breaks in 
DNA (213-215). For example, treating human respiratory 
tract tracheobronchial epithelial cells with gas-phase cigarette
proteins (such as hemoglobin), leaving hydrocarbon gases smoke produced DNA strand breakage and the formation of 
(ethane, pentane) and unsaturated aldehydes (malondialde- double-stranded DNA (216). Moreover, multiple chemical mod- 
hyde) as by-products (194). Methods for detecting and quanti- ifications (including guanine and adenine base deamination)
occurred in all four DNA bases in a pattern suggestive of reac­
tion with ’OH or deaminating species, such as H N 0 2, N 0 2, 
N2O3, and ONOO” in cigarette smoke (216). Hydroquinone 
as thiobarbituric and semiquinone radicals in cigarette smoke can also produce
oxyradicals that may nick DNA, causing mutations and, ulti­
mately, carcinogenesis (46,217).
Increased 8-hydroxy-2'-deoxyguanosine activity, a product 
of the reaction of oxidants and DNA, has been detected in the 
peripheral blood leukocytes of cigarette smokers and in lung 
epithelial cells exposed to cigarette smoke in vitro (218, 219). 
Likewise, oxidant-mediated DNA strand breaks occurred 
more frequently in mononuclear leukocytes exposed to acti­
vated PMN from cigarette smokers (220).
fying LPO in vitro and in vivo usually examine lipid peroxides 
or derived radicals directly or else detect lipid peroxide conju­
gates or decomposition products indirectly (194-198).
Lipid peroxidation products 
acid-reacting substances) were increased in the plasma and 
lung lavages of healthy cigarette smokers (24, 166, 199-206), 
and patients with emphysema, chronic bronchitis, and asthma 
(203-205). In addition, increased LPO products correlated in­
versely with the time elapsed from the last exposure to to­
bacco smoke and the degree of small airway obstruction in 
COPD patients (205). Cigarette smoke exposure produced 
lipid peroxidation in plasma in vitro (201 ). Lipid peroxidation 
occurred in cigarette smoke-exposed rat tracheal epithelium 
along with histochemical evidence of continuing production of 
both H20 2 and O2 at the apical cell membrane (207). LPO 
also occurred in lungs of animals exposed to cigarette smoke 
and sonicates of AM exposed to cigarette smoke in vitro (208).
Pentane and ethane exhalation were increased in cigarette These compounds exist in pulmonary tissue, circulating blood 
smokers (209, 210), and ethane exhalation was decreased by cells, and AM. 4-Hydroxy-l-(3-pyridyl)-l-butanone (HPB)-
O ther m a y
level of biologically relevant exposure to oxidants. Typical ex­
amples include polycylic aromatic hydrocarbon (PAH)-DNA 
adducts, which reflect exposure to tobacco smoke (221, 222).
antioxidant treatment (210). Notwithstanding these observa­
tions, some concern has persisted because of the difficulty in 
accurately measuring lipid peroxidation in vivo (211). This 
worry was mitigated recently by findings that plasma levels of dation processes in target cells, have been detected in lung tis- 
free and esterified F2-isoprostanes (a series of bioactive pros- sue and AM of cigarette smokers (223,224).
DNA adducts derived from metabolism of nicotine similarly
the amount of oxidative stress induced by cigarette 
smoke. Alkyl-DNA adducts, which may be formed during oxi-
taglandin F2-like compounds that are made by free radical cat- Finally, certain mutations be as
alyzed peroxidation of arachidonic acid) were increased in unique “fingerprints” of oxidative stress to DNA. Mutations 
smokers compared with nonsmokers (Figure 12) (212). More- of the p53 and K-m.v genes are both associated with cigarette 
over, free and esterified F2-isoprostane levels decreased follow- smoking, and the higher rate of lung cancer in cigarette smok­
ing smoking cessation for 2 wk. Additionally, plasma F2-isopros- ers suggests the damaging effects of oxidants on DNA (225, 
tanes were normal or only slightly increased in some cigarette 226). Although it has been suggested that benzo(a)pyrenes in
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tobacco smoke were related to certain mutations (GC TA 242). However, the effects of theophylline on oxygen radical
transversion), oxidation reactions may be involved, since simi- generation by PMN remain controversial (243-245). Incubat-
lar mutations develop following exposure to hyperoxia.
Carbonyl Proteins
Oxygen radicals can modify amino acid side chains, form pro­
tein aggregates, cleave peptide bonds, and make proteins 
more susceptible to proteolytic degradation (227). In the pro­
cess, some amino acid residues are converted to carbonyl de­
rivatives. Exposure to gas-phase cigarette smoke also modi­
fied human plasma proteins, producing carbonyl proteins with 
lost sulfhydryl groups (228, 229). In one study, the content of Corticosteroids
ing blood PMN from healthy volunteers with increasing con­
centrations of theophylline inhibited their oxygen radical pro­
duction in a dose-dependent fashion. Importantly, inhibition 
was reached at clinically achievable concentrations of theo­
phylline (244, 245). However, in other studies theophylline 
treatment enhanced O f  production by PMN (246, 247). 
Theophylline treatment also increased O f  release from eosi­
nophils from patients with peripheral eosinophilia (248).
oxidized proteins recovered by lung lavage was 0.59 ± 0.14 
nmol carbonyl/ml bronchoalveolar lavage fluid in asymptom­
atic smokers compared with 0.30 ± 0.07 nmol carbonyl/ml 
bronchoalveolar lavage fluid in nonsmoking control subjects
(230). Plasma protein sulfhydryls were also depleted following 
exposure to cigarette smoke in vitro. Reaction of proteins with 
nitric oxide or its derivatives may also lead to protein degrada­
tion (63). Furthermore, using a Trolox (vitamin E analog)- 
related assay, plasma antioxidant activity was decreased acutely 
in cigarette smokers, following acute exacerbations in COPD 
patients, and associated with protein sulfhydryl oxidation (107).
CONVENTIONAL TREATMENT AND OXIDATIVE 
STRESS IN COPD
Improving the quality and duration of life of COPD patients is 
a distinct challenge. The specific therapeutic goals are to re­
duce symptoms, preserve lung function, optimize gas ex­
change, and limit and/or treat acute exacerbations rapidly
(231). Because pulmonary function declines with aging, every­
thing must be done to prevent any additional functional loss 
caused by COPD. Indeed, elderly cigarette smokers who de­
velop COPD may lose as much as 80 ml of FEVj/yr compared 
with 33 ml/yr for nonsmokers (232).
The treatment for cigarette smoke-induced COPD has 
been reviewed extensively (233,234). In general, the accepted 
strategies encompass approaches that limit initiating and ag­
gravating triggers, such as tobacco smoke (smoking cessation) 
and inhalation of environmental and work-related irritants. 
More specific treatment consists of administering bronchodi- 
lators, antiinflammatory agents, and/or antibiotics. Additional 
approaches include nutritional supplementation, immuniza­
tion, breathing exercises, pulmonary rehabilitation, and ulti­
mately supplemental oxygen, given nocturnally or continu­
ously. Conventional therapies for COPD are discussed below, 
focusing on their potential effect on oxidant-antioxidant bal­
lt is still unclear whether inhaled corticosteroids attenuate 
COPD, even though several placebo-controlled clinical stud­
ies have addressed the question (249-255). However, steroids 
may have an antioxidant effect by decreasing the numbers as 
well as the oxidative and chemotactic responses of neutro­
phils. In one study, prolonged daily oral corticosteroid treat­
ment decreased the 0 ¿~ production and the chemotactic re­
sponsiveness of unstimulated, but not stimulated, peripheral 
blood PMN (256). In another study, 0¿” generation by PMN 
was decreased after in vivo prednisolone treatment in patients 
with emphysema (257). In another study, dexamethasone did 
not alter unstimulated O f  production by PMN either in vitro 
or in vivo (258). Likewise, inhaled corticosteroids did not 
change PMN numbers or IL-8 levels in the peripheral blood 
but did decrease the number of PMN in the sputum of COPD 
patients (259). Steroid therapy did not reduce eosinophil num­
bers or ECP levels in the sputum of COPD patients (260).
Antibiotics
«
Antibiotics used for treating chronic bronchitis would seem to 
have a certain role in reducing oxidative stress in COPD by re­
ducing infection and thereby lung inflammation. In addition, 
tetracycline and other anti-infectives may have independent 
antioxidant properties.
Miscellaneous Drugs
Nedocromil sodium inhibited O f  production by PMN in vitro 
(261). Ambroxol is an expectorant with antioxidant properties 
that stimulates the formation and release of surfactant by type 
II pneumocytes (262,263). Inhaled NO (40 ppm) had no effect 
on respiratory system resistance in patients with COPD or 
healthy subjects (264).
ANTIOXIDANT THERAPY
N-acelylcysteine (NAC) is the most widely investigated drug 
with antioxidant properties that has been used in both experi­
mental and clinical settings which are relevant to COPD (265- 
267). Although given initially because of its mucolytic proper­
ties, NAC is a thiol-containing compound that may act as an 
antioxidant by providing cysteine intracellularly for the en­
hanced production of GSH (268). This potentially beneficial 
antioxidant effect is suggested because NAC decreased H20 2- 
induced damage to epithelial cells in vitro (269) and NFkB 
activation in some cells (270). In addition, NAC treatment re­
duced cigarette smoke-induced abnormalities in PMN (271), 
AM, fibroblasts, and epithelial cells in vitro (272-275). NAC 
treatment also attenuated rat secretory cell hyperplasia in­
well (238-240). For example, O f  production by AM was de- dueed by tobacco smoke (276) and prevented HOCl-mcdiated
Smoking Cessation
It is not surprising that the rates of decline in lung function in 
smokers with mild COPD were reduced by smoking cessation, 
since smoking cessation potentially decreases most sources of 
oxidative stress. A prime example of this possibility was the 
finding that smoking cessation for 6 mo reduced the numbers 
of AM and PMN recoverable by lung lavage (235-237).
Sympathomimetics/Anticholinergics/Methylxanthines
While the primary effect of ß2 agonists is to relax airway 
smooth muscle, some antioxidant benefits may be provided as
creased in chronic bronchitis patients treated with formoterol, 
and terbutaline reduced 0¿~ generation by AM in vitro (241,
inactivation of ex¡-proteinase inhibitor in vitro (277). NAC 
treatment may alter lung oxidant-antioxidant imbalance in
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humans (278). NAC given orally increased lung lavage GSH 
levels (279), reduced 0¿-  production by AM recovered by lav­
age (273), and decreased lung lavage PMN chemiluminescence 
in vitro (280). However, peripheral blood PMN obtained from 
healthy nonsmokers treated with NAC produced normal 
amounts of H20 2 (273).
The clinical efficacy of NAC has been investigated in a 
number of studies of patients with chronic bronchitis, with and 
without COPD. Treatment with NAC caused symptomatic 
improvement in COPD patients, reflected by decreased spu­
tum viscosity and purulence and improved sputum expectora­
tion (281). In addition, NAC treatment reduced the number of 
exacerbations and sick-leave days in some (282, 283), but not 
other (284-286), investigations of COPD patients. Parentheti­
cally, NAC treatment also decreased the number of viral in­
fections (287, 288) and airway bacterial colonization (289) in 
patients with COPD. In a recent investigation in Sweden, the 
decline in FEVx in COPD patients who took NAC for 2 yr was 
less than in a reference group (Figure 13) (290). This favorable 
effect of NAC was particularly apparent in COPD patients 
over 50 yr of age (yearly decline of 30 ml in FEVj) compared 
with the reference group (yearly decline of 54 ml in FEVj).
CONCLUSIONS
COPD is a costly health problem (291). As reviewed herein, a 
myriad of evidence suggests that oxidative stress contributes 
to COPD (Figure .14) (292). Nonetheless, obtaining definitive 
proof that oxidants contribute to COPD and/or that antioxi­
dant therapy is beneficial in COPD remains problematic. In­
deed, because COPD is a chronic, progressive disease, long­
term study of many patients would be required. Furthermore, 
evaluation is complicated because of coincident decreases in 
pulmonary function related to aging and other maladies. Clin­
ical investigations must also account for variations in the dura-
deoxyguanosine)
Antioxidant 
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NFkB
activation
inflammation
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COPD
Figure 14. Cigarette smoke, oxidative stress, and COPD. Numer­
ous processes increase lung oxidative stress and contribute to a va­
riety of abnormalities that contribute to COPD.
It should be possible to gain meaningful information from 
studies using surrogate markers that reflect oxidative status 
(295). If an acceptable marker of oxidative stress increased in 
COPD patients and correlated with either an increased rate of 
pulmonary dysfunction and/or the severity of COPD, then the 
association between oxidants and COPD would be strength­
ened. Likewise, if antioxidant therapy decreased both the 
marker and meaningful endpoints, then the role of oxidants 
and the value of antioxidant therapy in COPD would be fur­
ther supported, even if there was no significant effect on mor­
tality or FEV] during the short-term analyses. Finally, if these 
approaches could be applied to subpopulations of individuals 
who have rapid declines in FEV], then a definitive answer to 
this important premise might be secured even more rapidly.
It is obvious from this review that lung oxidant-antioxidant 
balance is abnormal in cigarette smokers (Figure 14). How­
ever, it remains unclear why only certain cigarette smokers
tion of smoking, daily smoking consumption, and smoking (actually a minority) develop COPD and, for that matter,
cessation, as well as for other confounding factors, such as car- lung cancer and atherosclerosis. Exposure to inhaled oxidants
diovascular disease and cancer. Suitable endpoints are also dif- from cigarette smoke would seem to be fairly consistent
ficult because objective decreases in FEV] and mortality do not among individuals with comparable smoking histories. The
change sufficiently in the short term. Other changes, such as answer to this intriguing question lies in an improved under­
exacerbations and sick days, which occur more rapidly, are not standing of the nature of the oxidant-antioxidant balance and
as convincing because of their subjectivity. Not surprisingly, the genetic factors and other intrinsic factors, including di-
for the aforementioned reasons, none of the presently used etary factors, that control this balance (296). Unfortunately,
short-term therapies, such as antibiotics or steroids, has been because of the great variability that exists in the individuals
shown to unequivocally improve FEVj or survival in COPD. who smoke and difficulties in measuring oxidative status,
So far, appreciable improvement in declines in FEVj has been many challenges remain in understanding, treating, and pre­
found in COPD patients only after smoking cessation (293,294). venting COPD.
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